Apart from MED15-TFE3 fusion tRCC, nearly two-thirds (63.5%, 40/63) of TFE3-tRCCs in our cohort exhibited type 1 TIME19, characterized by a low CD8 + T-cells infiltration and low PD-L1 expression in tumors (Fig. 4I). This evidence concerns the gene MED15 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.